Strategic Intelligence: Pharma M&A Deals Q3 2024 - Top Themes
Summary
This report analyzes the disruptive themes that have driven M&A activity in Q3 2024 in the pharma Sector.
The global pharma sector in Q3 2024 witnessed deals worth $35 billion, a decline of 3% compared to Q3 2023. In terms of deal volume, there was a rise of 11% to record 279 M&A deals in Q3 2024. The Pharma sector recorded 12 mega deals (defined as any deal valued at more than $1 billion) in Q3 2024, an increase of 71% compared to Q3 2023.
Scope
- This report provides an overview of merger and acquisition activity globally in Q3 2024 in Pharma Sector
- It identifies the themes driving most notable to deals announced in Q3 2024 in the Pharma Sector
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
- Executive Summary
- Review of Pharma M&A Market - Q3 2024
- Top Pharma M&A Deals by Sector - Q3 2024
- Pharma M&A Deals Analysis by Geography - Q3 2024
- Top Themes Driving Pharma M&A Activity - Q3 2024
- Appendix 1: Deal Selection Criteria
- Appendix 2: Top Themes for 2024 in Pharma
- Appendix 3: Thematic Research Methodology
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook